All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
With a pivotal trial slated to start next quarter for lead immunotherapy candidate AGS-003 in metastatic renal cell carcinoma, Argos Therapeutics Inc. decided to take a chance on the initial public offering (IPO) market, which, after a couple of dry months, seems to be picking back up again.